Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liquid biopsy study of resistance to EGFR TKIs in EGFR-mutant non-small cell lung cancer
2016-001335-12Phase 2Completed
- Sponsor
- Hellenic Oncology Research Group
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Hellenic Oncology Research Group. Started Apr 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-001335-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001335-12.